Decision day for lecanemab
Should lecanemab receive a green light from the FDA, it would be the second new Alzheimer’s therapy to come to market in two years.
Source: politico.com
Stay updated with breaking news from Jon Heppen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Should lecanemab receive a green light from the FDA, it would be the second new Alzheimer’s therapy to come to market in two years.
Nearly 94 percent of people with substance use disorder didn’t receive any treatment in 2021.